A multicenter observational study of incretin-based drugs and heart failure

New England Journal of Medicine

Volumn 374, Issue 12, 2016, Pages 1145-1154

  Filion, Kristian B ^a,b   Azoulay, Laurent ^a,b   Platt, Robert W ^b,c   Dahl, Matthew ^d   Dormuth, Colin R ^f   Clemens, Kristin K ^g   Hu, Nianping ^h   Paterson, J Michael ^i,j,l   Targownik, Laura ^d,e   Turin, Tanvir C ^m   Udell, Jacob A ^i,k   Ernst, Pierre ^a,b   Ma, Zhihai ⁿ   Zhang, Jianguo ⁿ   Carney, Gregory A ⁿ   Coulombe, Janie ⁿ   Yin, Hui ⁿ   Wu, Caixia Fangyun ⁿ   Hollands, Simon ⁿ   Jin, Shan ⁿ   Mizrahi, Corine ^o   Dahan, Melissa ^o   Sang, Laura ^o   Pang, Menglan ⁿ   Durand, Madeleine ⁿ   Cardinal, Héloïse ⁿ   Suissa, Karine ⁿ   more..

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h Health Quality Council   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY HEALTH NETWORK   (Canada)

^l MCMASTER UNIVERSITY   (Canada)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ NONE

^o NONE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DRUG COMBINATION;

ADULT; AGE; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84962323033     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506115     Document Type: Article

References (22)

1. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356-66.
2. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
3. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579-88.
4. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35.
5. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
6. Yu OH, Filion KB, Azoulay L, Patenaude V, Majdan A, Suissa S. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 2015; 38: 277-84.
7. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014; 2: 573-82.
8. Wang KL, Liu CJ, Chao TF, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 2014; 177: 86-90.
9. Velez M, Peterson EL, Wells K, et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 2015; 21: 2-8.
10. Chen DY, Wang SH, Mao CT, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol 2015; 181: 200-6.
11. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012; 6(4):e134-40.
12. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: congestive heart failure report. Silver Spring, MD: Food and Drug Administration, 2010 (http://www.mini-sentinel.org/work-products/HealthOutcomes/MS-HOI-CHFReport.pdf).
13. Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 2012; 21: Suppl 1: 129-40.
14. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-76.
15. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013; 166(6): 983-9.e7.
16. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5.
17. Suissa S. Novel approaches to pharma-coepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. New York: Wiley, 2005: 811-29.
18. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-22.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
21. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
22. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157: 601-10.